Ariad Pharmaceuticals Company Profile (NASDAQ:ARIA)

Analyst Ratings

Consensus Ratings for Ariad Pharmaceuticals (NASDAQ:ARIA) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.57)
Consensus Price Target: $9.14 (12.74% upside)

Analysts' Ratings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Show:
DateFirmActionRatingPrice TargetActions
6/22/2016Jefferies GroupReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016Royal Bank Of CanadaReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016Cowen and CompanyReiterated RatingOutperform$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016JMP SecuritiesReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/24/2016William BlairReiterated RatingBuy$10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2016Barclays PLCReiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016JPMorgan Chase & Co.Reiterated RatingOutperform$11.00 -> $9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman Sachs Group Inc.Lower Price Target$7.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/5/2015HC WainwrightReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2015BMO Capital MarketsReiterated RatingOutperform$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/16/2015Stifel NicolausReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/11/2014Credit Suisse Group AGDowngradeNeutral -> Underperform$8.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/6/2014Chardan CapitalReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/8/2014Citigroup Inc.Reiterated RatingSell$7.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016Q216($0.11)$60.64 millionListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/10/2016Q116($0.27)($0.23)$43.06 million$35.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q415($0.32)($0.32)$44.79 million$36.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.23)($0.29)$46.09 million$27.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.27)($0.33)$33.24 million$27.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.27)($0.28)$27.26 million$23.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/19/2015Q414($0.20)($0.03)$39.50 million$66.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q314$0.30($0.27)$16.50 million$14.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.29)($0.30)$13.65 million$12.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014Q114($0.32)($0.27)$10.41 million$11.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2014Q413($0.47)($0.40)$6.31 million$8.28 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013Q313($0.43)($0.36)$16.67 million$16.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013($0.40)($0.37)$11.11 million$13.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.38)($0.36)$5.01 million$6.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2013Q4 2012($0.36)($0.36)$78.00 million$0.07 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.32)($0.32)$0.96 million$0.85 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.27)($0.31)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2012($0.23)($0.35)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/28/2012($0.20)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2011$0.02$0.10ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2011($0.16)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2011($0.13)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2011($0.14)($0.25)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ariad Pharmaceuticals (NASDAQ:ARIA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.34)($0.17)($0.27)
Q2 20162($0.11)($0.09)($0.10)
Q3 20162($0.22)($0.19)($0.21)
Q4 20162($0.18)($0.11)($0.15)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ariad Pharmaceuticals (NASDAQ:ARIA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Ariad Pharmaceuticals (NASDAQ:ARIA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/28/2016Hugh M ColeSVPSell6,012$7.05$42,384.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2016Timothy P ClacksonInsiderSell23,999$7.28$174,712.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2016Athanese LavidasDirectorSell76,250$8.21$626,012.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2016Massimo RadaelliDirectorSell108,569$8.25$895,694.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2016Timothy P ClacksonInsiderSell17,762$8.08$143,516.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2016Paris PanayiotopoulosCEOBuy26,990$7.41$199,995.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/2/2016Timothy P ClacksonInsiderSell11,700$7.13$83,421.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/22/2016Timothy P ClacksonInsiderSell21,409$7.37$157,784.33View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/22/2016Timothy P ClacksonInsiderSell23,834$6.58$156,827.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2016David L BersteinSVPSell2,375$6.47$15,366.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2016Edward M FitzgeraldVPSell5,417$6.47$35,047.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2016Frank HaluskaCMOSell3,575$6.47$23,130.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2016Maria E CantorSVPSell3,575$6.46$23,094.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2016Martin J DuvallEVPSell4,000$6.47$25,880.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2016Timothy P ClacksonInsiderSell5,417$6.47$35,047.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Daniel M BollagVPSell9,625$6.11$58,808.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Frank HaluskaCMOSell10,588$6.11$64,692.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Timothy P ClacksonInsiderSell34,672$6.03$209,072.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Edward M. FitzgeraldCFOSell14,667$4.81$70,548.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Maria E. CantorSVPSell16,133$4.82$77,761.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/1/2016Paris PanayiotopoulosCEOBuy61,099$4.91$299,996.09View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015David L. BersteinSVPSell5,000$6.46$32,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Frank HaluskaCMOSell5,500$6.46$35,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Timothy P. ClacksoninsiderSell8,750$6.46$56,525.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Maria E CantorSVPSell2,696$9.11$24,560.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Edward M FitzgeraldCFOSell32,858$10.00$328,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Maria E CantorSVPSell1,268$10.00$12,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015David L BersteinSVPSell4,000$8.54$34,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015Edward M FitzgeraldCFOSell7,000$8.54$59,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015Frank HaluskaCMOSell4,400$8.54$37,576.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015Martin J DuvallEVPSell1,400$8.54$11,956.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2015Edward M FitzgeraldCFOSell60,000$8.80$528,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/23/2015Timothy P ClacksonInsiderSell123,766$9.50$1,175,777.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Daniel M BollagVPSell7,000$8.72$61,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Edward M FitzgeraldCFOSell9,584$8.72$83,572.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Frank HaluskaCMOSell6,875$8.71$59,881.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Maria E CantorSVPSell16,954$8.86$150,212.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Martin J DuvallEVPSell4,834$8.80$42,539.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Timothy P ClacksonInsiderSell32,741$8.88$290,740.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2015Harvey J M D BergerCEOBuy25,000$6.83$170,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Frank HaluskaCMOSell16,134$6.33$102,128.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/23/2015Harvey J M D BergerCEOBuy25,000$6.17$154,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/14/2015Sarah J SchlesingerDirectorBuy2,600$6.61$17,186.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Harvey J M D BergerCEOBuy25,000$6.35$158,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2014Sarah J SchlesingerDirectorBuy2,600$6.09$15,834.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Maria E CantorSVPSell1,749$7.00$12,243.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2014Harvey J M D BergerCEOBuy25,000$6.15$153,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Sarah J SchlesingerDirectorBuy2,600$6.26$16,276.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Sarah J SchlesingerDirectorBuy5,200$5.73$29,796.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Alexander J DennerDirectorBuy850,000$5.83$4,955,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Daniel BollagVPSell2,400$8.22$19,728.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Frank HaluskaCMOSell3,400$8.21$27,914.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Maria CantorSVPSell4,250$8.21$34,892.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2014Timothy ClacksonInsiderSell6,500$8.21$53,365.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Daniel BollagVPSell2,400$7.89$18,936.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014David BersteinSVPSell1,600$7.89$12,624.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2014Timothy ClacksonInsiderSell6,667$7.89$52,602.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2013David BersteinVPSell4,500$5.14$23,130.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2013Frank HaluskaCMOSell5,100$5.14$26,214.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2013Maria CantorSVPSell6,375$5.14$32,767.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/19/2013Timothy ClacksonInsiderSell9,750$5.14$50,115.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/6/2013Timothy P ClacksonInsiderSell8,449$22.00$185,878.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Harvey BergerCEOSell118,759$18.34$2,178,040.06View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2013Frank HaluskaCMOSell6,400$19.79$126,656.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2013Maria E CantorSVPSell8,000$19.79$158,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2013Timothy P ClacksonInsiderSell14,000$19.79$277,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2013Harvey J M D BergerCEOSell199,400$19.84$3,956,096.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/19/2013Harvey J M D BergerCEOSell11,200$18.00$201,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Harvey J M D BergerCEOSell92,498$18.10$1,674,213.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/26/2013Edward M FitzgeraldCFOSell12,933$18.75$242,493.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2013Daniel M BollagVPSell12,933$18.87$244,045.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2013Frank HaluskaCMOSell5,333$18.88$100,687.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2013Pierre F DodionSVPSell8,133$18.87$153,469.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2013Timothy P ClacksonInsiderSell19,167$18.87$361,681.29View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2013Harvey J M D BergerCEOSell105,400$22.05$2,324,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/21/2012Athanese LavidasDirectorSell10,500$20.31$213,255.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Ariad Pharmaceuticals (NASDAQ:ARIA)
DateHeadline
07/23/16 05:37 AMNotable Research Reports: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), 3D Systems Corporation (NYSE:DDD) - Review Fortune
07/23/16 05:37 AMARIAD Pharmaceuticals Inc. (ARIA) is Trading Higher on Unusual Volume for July 21 - Equities.com
07/22/16 07:34 PMIntraday Movers: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Mylan NV (NASDAQ:MYL) - NYSE Journal (press release)
07/22/16 07:34 PMStocks Recommendation Update: ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) , Eleven Biotherapeutics, Inc ... - Street Updates
07/22/16 03:07 PMARIAD PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Financial Statemen -
07/22/16 02:33 PMBiotech Stocks Worth a Closer Look: Ariad Pharmaceuticals (NASDAQ:ARIA), Biogen (NASDAQ:BIIB) - The Voice Registrar
07/22/16 07:03 AMARIAD Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ARIA-US : July 22, 2016 -
07/21/16 02:33 PMBiotech Stocks Worth a Closer Look: Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), Ariad Pharmaceuticals Inc ... - The Voice Registrar
07/21/16 02:33 PMAnalysts Actions to Track: ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) , GlaxoSmithKline PLC (NYSE:GSK) - Street Updates
07/21/16 02:33 PMBiotechnology Stocks under Discussion: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Gilead Sciences, Inc. (NASDAQ ... - Post Registrar
07/21/16 02:33 PMStocks on the Run: Ariad Pharmaceuticals, Inc.(NASDAQ:ARIA), Texas Instruments Incorporated(NASDAQ:TXN) - NYSE Journal (press release)
07/21/16 09:43 AMARIAD Pharmaceuticals Inc. (ARIA) Jumps 8.23% on July 20
07/21/16 07:00 AMAriad Pharmaceuticals (ARIA) In Focus: Stock Jumps 8.2% -
07/20/16 10:02 PMPreview of Analysts Recommendation: Astrazeneca PLC (NYSE:AZN) , ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Street Updates
07/20/16 10:02 PMARIAD Pharmaceuticals Inc. (ARIA) Jumps 8.23% on July 20 - Equities.com
07/20/16 10:41 AMBellicum Pharmaceuticals Announces Patent on CaspaCIDe Method for Selectively Eliminating Therapeutic Cells
07/19/16 02:35 PMHC Stocks in Hub: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) - share market updates (press release)
07/19/16 08:46 AMARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Updated Price Targets - FTSE News
07/19/16 08:46 AMEquity Roundup: Stock Performance Focus on ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Press Telegraph
07/19/16 08:46 AMAriad Pharmaceuticals Inc versus Five Prime Therapeutics Inc Head to Head Compare - CML News
07/18/16 02:37 PMIs $13 Price Target Attainable For ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA)? - Investor Newswire
07/18/16 02:37 PMEarnings Estimates Analysis: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - News Oracle
07/18/16 07:28 AMHC Stocks Outlines: Great Basin Scientific Inc (NASDAQ:GBSN) Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) - share market updates (press release)
07/16/16 02:32 PMTrading the Biotech News: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Voice Registrar
07/15/16 06:52 PMAriad moving to new Kendall Square headquarters
07/14/16 02:36 PMLatest Stock's Price Updates: Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) , ARIAD Pharmaceuticals, Inc ... - Street Updates
07/14/16 11:27 AMInvesting in Cures for Cancer: GE Poised to Lead Industrialization of Cell Therapy Industry with Acquisition of Biosafe Group SA
07/14/16 11:27 AMVirginia Cancer Specialists First in the World to Enroll Patient in Cutting-Edge Lung Cancer Clinical Trial
07/13/16 10:39 AMBiotech Stocks Worth a Closer Look: Exelixis, Inc. (NASDAQ:EXEL), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - The Voice Registrar
07/12/16 06:16 AMShares Moving Up Over the Past Quarter: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - Engelwood Daily
07/11/16 02:34 PMStrong Sell Calls For ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) At 1 - Investor Newswire
07/11/16 07:23 AMCompany Stock Focus for ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA): Which Way Will Shares Head? - Press Telegraph
07/11/16 07:23 AMStock on the Rise for the Quarter: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - Engelwood Daily
07/11/16 07:23 AMCompany Shares of ARIAD Pharmaceuticals (NASDAQ:ARIA) Rally 0.27% - Trade Calls
07/11/16 07:23 AMStock Performance Rundown on: Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - Press Telegraph
07/10/16 07:20 AMWere Analysts Bullish Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) This Week? - Engelwood Daily
07/09/16 02:31 PMAriad Pharmaceuticals Incorporated (NASDAQ:ARIA) Sellers Increased By 6.7% Their Shorts - Press Telegraph
07/08/16 02:35 PMHC Stocks Indications: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Allergan plc Ordinary Shares (NYSE:AGN) - share market updates (press release)
07/08/16 02:35 PMLast Analysts Rating Review: Novavax, Inc. (NASDAQ:NVAX) , ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Street Updates
07/07/16 02:35 PMStocks inside Analysts Limelight: Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) , ARIAD Pharmaceuticals, Inc ... - Street Updates
07/07/16 10:29 AMStock Tracking Down This Month; Investor Alert on Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - Engelwood Daily
07/07/16 10:29 AMARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/06/16 08:19 PMInsiders are Gradually Selling Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) - Telanagana Press
07/06/16 02:34 PMBroker Outlook For ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Fiscal Standard
07/06/16 07:23 AMStock Rating Watch and Earnings Insight for ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) - Press Telegraph
07/06/16 07:23 AMAriad Pharmaceuticals Inc. Stock Hits Elevated Volatility Level - CML News
07/05/16 02:32 PMCan ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Improve on the Earnings Front? - Engelwood Daily
07/05/16 07:20 AMARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Expected to Reach Highs Of $13 - Investor Newswire
07/05/16 07:20 AMHC Stocks in Front Line: Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), Hologic, Inc. (NASDAQ:HOLX) - share market updates (press release)
07/05/16 06:35 AMARIAD to Webcast Conference Call on Second Quarter 2016 Financial Results - [Business Wire] - ARIAD Pharmaceuticals, Inc. today announced that it will report its second quarter 2016 financial results on Thursday, July 28, 2016, before the market opens. Following the announcement, at 8:30 a.m.

Social

About Ariad Pharmaceuticals

Ariad Pharmaceuticals logoARIAD Pharmaceuticals, Inc. (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company's product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company's Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Its Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). Its AP32788 is a TKI, which is designed as a targeted therapy for patients with non-small cell lung cancer (NSCLC) with specific mutations in two kinases, epidermal growth factor receptor (EGFR), or human epidermal growth factor receptor 2 (HER2). Its Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ARIA
  • CUSIP: 04033A10
Key Metrics:
  • Previous Close: $7.98
  • 50 Day Moving Average: $7.67
  • 200 Day Moving Average: $6.67
  • P/E Ratio: N/A
  • P/E Growth: -0.33
  • Market Cap: $1.55B
  • Beta: 1.9
  • Current Year EPS Consensus Estimate: $-0.72 EPS
  • Next Year EPS Consensus Estimate: $-0.59 EPS
Additional Links:
Ariad Pharmaceuticals (NASDAQ:ARIA) Chart for Saturday, July, 23, 2016